GRI Bio reported financial results for Q2 2024, with a net loss of $2.25 million compared to $6.75 million in Q2 2023. Research and development expenses remained stable at $0.9 million, while general and administrative expenses decreased to $1.4 million from $5.1 million year-over-year. The company ended the quarter with $6.4 million in cash and cash equivalents.The company made significant progress in its clinical programs, particularly with GRI-0621 for idiopathic pulmonary fibrosis (IPF). Patient enrollment continues in the Phase 2a biomarker study, with interim data expected in Q4 2024 and topline results in Q1 2025. Additionally, GRI Bio received UK regulatory approval to expand the IPF trial internationally.During Q2, GRI Bio strengthened its financial position through multiple equity offerings, including a $4.4 million public offering in February and a $3.2 million offering in June 2024. The company also established an At-The-Market facility and regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements. Management believes current cash will fund operations into Q1 2025.

GRI Bio reported financial results for Q2 2024, with a net loss of $2.25 million compared to $6.75 million in Q2 2023. Research and development expenses remained stable at $0.9 million, while general and administrative expenses decreased to $1.4 million from $5.1 million year-over-year. The company ended the quarter with $6.4 million in cash and cash equivalents.The company made significant progress in its clinical programs, particularly with GRI-0621 for idiopathic pulmonary fibrosis (IPF). Patient enrollment continues in the Phase 2a biomarker study, with interim data expected in Q4 2024 and topline results in Q1 2025. Additionally, GRI Bio received UK regulatory approval to expand the IPF trial internationally.During Q2, GRI Bio strengthened its financial position through multiple equity offerings, including a $4.4 million public offering in February and a $3.2 million offering in June 2024. The company also established an At-The-Market facility and regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements. Management believes current cash will fund operations into Q1 2025.